YAP1 expression in colorectal cancer confers the aggressive phenotypes via its target genes

References

• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017 May 6;67(3):177–193. doi: 10.3322/caac.21395
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016 Mar-Apr;66(2):115–32.
   PubMed Web of Science ®Google Scholar
• Strum WB, Longo DL. Colorectal adenomas. N Engl J Med. 2016 Mar 17;374(11):1065–75. doi: 10.1056/NEJMra1513581
   PubMed Web of Science ®Google Scholar
• Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015 Feb;15(2):73–79. doi: 10.1038/nrc3876
   PubMed Web of Science ®Google Scholar
• Hong AW, Meng Z, Guan KL. The hippo pathway in intestinal regeneration and disease. Nat Rev Gastroenterol Hepatol. 2016 Jun;13(6):324–37. doi: 10.1038/nrgastro.2016.59
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang L, Purohit V, et al. Active YAP promotes pancreatic cancer cell motility, invasion and tumorigenesis in a mitotic phosphorylation-dependent manner through LPAR3. Oncotarget. 2015 Nov 3;6(34):36019–31. doi: 10.18632/oncotarget.5935
   PubMedGoogle Scholar
• Lee KW, Lee SS, Kim SB, et al. Significant association of oncogene YAP1 with poor prognosis and cetuximab resistance in colorectal cancer patients. Clin Cancer Res. 2015 Jan 15;21(2):357–64. doi: 10.1158/1078-0432.CCR-14-1374
   PubMed Web of Science ®Google Scholar
• Di Benedetto A, Mottolese M, Sperati F, et al. The hippo transducers TAZ/YAP and their target CTGF in male breast cancer. Oncotarget. 2016 Jul 12;7(28):43188–43198. doi: 10.18632/oncotarget.9668
   PubMed Web of Science ®Google Scholar
• Perra A, Kowalik MA, Ghiso E, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014 Nov;61(5):1088–96.
   PubMed Web of Science ®Google Scholar
• Pei T, Li Y, Wang J, et al. YAP is a critical oncogene in human cholangiocarcinoma. Oncotarget. 2015 Jul 10;6(19):17206–20. doi: 10.18632/oncotarget.4043
   PubMedGoogle Scholar
• Bosurgi L, Bernink JH, Delgado Cuevas V, et al. Paradoxical role of the proto-oncogene axl and mer receptor tyrosine kinases in colon cancer. Proc Natl Acad Sci USA. 2013 Aug 6;110(32):13091–6. doi: 10.1073/pnas.1302507110
   PubMed Web of Science ®Google Scholar
• Lin MT, Zuon CY, Chang CC, et al. Cyr61 induces gastric cancer cell motility/invasion via activation of the integrin/nuclear factor-kappaB/cyclooxygenase-2 signaling pathway. Clin Cancer Res. 2005 Aug 15;11(16):5809–5820. doi: 10.1158/1078-0432.CCR-04-2639
   PubMed Web of Science ®Google Scholar
• Ladwa R, Pringle H, Kumar R, et al. Expression of CTGF and Cyr61 in colorectal cancer. J Clin Pathol. 2011 Jan;64(1):58–64.
   PubMed Web of Science ®Google Scholar
• Yokota M, Kojima M, Higuchi Y, et al. Gene expression profile in the activation of subperitoneal fibroblasts reflects prognosis of patients with colon cancer. Int J Cancer. 2016 Mar 15;138(6):1422–31. doi: 10.1002/ijc.29851
   PubMed Web of Science ®Google Scholar
• Yuan H, Wei R, Xiao Y, et al. RHBDF1 regulates APC-mediated stimulation of the epithelial-to-mesenchymal transition and proliferation of colorectal cancer cells in part via the Wnt/beta-catenin signalling pathway. Exp Cell Res. 2018 Jul 1;368(1):24–36. doi: 10.1016/j.yexcr.2018.04.009
   PubMed Web of Science ®Google Scholar
• Sun Z, Xu R, Li X, et al. Prognostic value of yes-associated protein 1 (YAP1) in various cancers: a meta-analysis. PLoS One. 2015;10(8):e0135119. doi: 10.1371/journal.pone.0135119
   PubMed Web of Science ®Google Scholar
• Hong SA, Son MW, Cho J, et al. Low angiomotin-p130 with concomitant high yes-associated protein 1 expression is associated with adverse prognosis of advanced gastric cancer. APMIS. 2017 Nov;125(11):996–1006.
   PubMed Web of Science ®Google Scholar
• Zhang L, Song X, Li X, et al. Yes-associated protein 1 as a novel prognostic biomarker for gastrointestinal cancer: a meta-analysis. Biomed Res Int. 2018;2018:4039173. doi: 10.1155/2018/4039173
   PubMed Web of Science ®Google Scholar
• Cho SY, Gwak JW, Shin YC, et al. Expression of hippo pathway genes and their clinical significance in colon adenocarcinoma. Oncol Lett. 2018 Apr;15(4):4926–4936.
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015 Nov 5;163(4):811–28. doi: 10.1016/j.cell.2015.10.044
   PubMed Web of Science ®Google Scholar
• Gregorieff A, Wrana JL. Hippo signalling in intestinal regeneration and cancer. Curr Opin Cell Biol. 2017 Oct;48:17–25. doi: 10.1016/j.ceb.2017.04.005
   PubMed Web of Science ®Google Scholar
• van Rensburg HJ J, Yang X. The roles of the hippo pathway in cancer metastasis. Cell Signal. 2016 Nov;28(11):1761–1772. doi: 10.1016/j.cellsig.2016.08.004
   PubMed Web of Science ®Google Scholar
• Wei X, Ye J, Shang Y, et al. Ascl2 activation by YAP1/KLF5 ensures the self-renewability of colon cancer progenitor cells. Oncotarget. 2017 Dec 12;8(65):109301–109318. doi: 10.18632/oncotarget.22673
   PubMedGoogle Scholar
• Shao DD, Xue W, Krall EB, et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell. 2014 Jul 3;158(1):171–84. doi: 10.1016/j.cell.2014.06.004
   PubMed Web of Science ®Google Scholar
• Rosenbluh J, Nijhawan D, Cox AG, et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012 Dec 21;151(7):1457–1473. doi: 10.1016/j.cell.2012.11.026
   PubMed Web of Science ®Google Scholar
• Mo JS, Park HW, Guan KL. The hippo signaling pathway in stem cell biology and cancer. EMBO Rep. 2014 Jun;15(6):642–656. doi: 10.15252/embr.201438638
   PubMed Web of Science ®Google Scholar
• Fujii M, Toyoda T, Nakanishi H, et al. TGF-beta synergizes with defects in the hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012 Mar 12;209(3):479–494. doi: 10.1084/jem.20111653
   PubMed Web of Science ®Google Scholar
• Pobbati AV, Hong W. Emerging roles of TEAD transcription factors and its coactivators in cancers. Cancer Biol Ther. 2013 May;14(5):390–8. doi: 10.4161/cbt.23788
   PubMed Web of Science ®Google Scholar
• Ye J, Wei X, Shang Y, et al. Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity. Oncogene. 2017 Nov 16;36(46):6391–6407. doi: 10.1038/onc.2017.241
   PubMed Web of Science ®Google Scholar